EcoR1 Capital LLC Buys 3,332,544 Shares of Voyager Therapeutics, Inc. $VYGR

EcoR1 Capital LLC grew its stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 497.2% in the fourth quarter, Holdings Channel reports. The fund owned 4,002,847 shares of the company’s stock after acquiring an additional 3,332,544 shares during the quarter. Voyager Therapeutics accounts for about 0.7% of EcoR1 Capital LLC’s portfolio, making the stock its 20th largest position. EcoR1 Capital LLC owned approximately 0.07% of Voyager Therapeutics worth $15,731,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of VYGR. Wexford Capital LP bought a new position in Voyager Therapeutics in the 3rd quarter worth approximately $42,000. ProShare Advisors LLC bought a new position in shares of Voyager Therapeutics in the fourth quarter worth $44,000. CIBC Asset Management Inc purchased a new stake in shares of Voyager Therapeutics during the 4th quarter valued at $45,000. Coldstream Capital Management Inc. purchased a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at $55,000. Finally, EHP Funds Inc. purchased a new stake in shares of Voyager Therapeutics during the 3rd quarter valued at $58,000. 48.03% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Wall Street Zen cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright reiterated a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, May 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Wednesday, April 15th. Finally, Truist Financial upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Voyager Therapeutics Stock Up 2.5%

Shares of Voyager Therapeutics stock opened at $3.62 on Thursday. The firm has a market cap of $218.72 million, a PE ratio of -1.84 and a beta of 1.25. Voyager Therapeutics, Inc. has a 12-month low of $2.83 and a 12-month high of $5.55. The company’s fifty day simple moving average is $3.81 and its two-hundred day simple moving average is $3.93.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. The business had revenue of $1.19 million for the quarter, compared to analyst estimates of $8.79 million. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. As a group, sell-side analysts expect that Voyager Therapeutics, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 11,511 shares of the firm’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total value of $44,547.57. Following the sale, the chief executive officer owned 472,549 shares of the company’s stock, valued at $1,828,764.63. This trade represents a 2.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 12.70% of the stock is currently owned by company insiders.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.